Strength, Aging, and Memory in Prostate Cancer
NCT04852224, Completed, University of Nebraska
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Strength, Aging, and Memory in Prostate Cancer | ClinicalTrials.gov |
| NCT number | NCT04852224 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 20 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Nebraska | ClinicalTrials.gov |
| Conditions | Prostate Neoplasm, Prostate Cancer | ClinicalTrials.gov |
| First posted | 2021-04-21 | ClinicalTrials.gov |
| Last updated | 2024-09-19 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in inhibitory control | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in interference score on Stroop task, with negative values indicating lower inhibitory control. The Stroop task interference score is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Primary | Change in cognitive flexibility | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in reaction time on Task-switch task, with higher values indicating lower cognitive flexibility. The Task-switch reaction time is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Primary | Change in executive function | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in completion time on Trails B task, with higher values indicating lower executive function. Trails B completion time is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Primary | Change in spatial working memory reaction time | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in reaction time on spatial working memory task, with faster reaction times indicating better spatial working memory. | ClinicalTrials.gov |
| Primary | Change in short term memory | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in accuracy on N-Back task, with higher accuracy indicating better short-term memory. | ClinicalTrials.gov |
| Primary | Change in processing speed | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in accuracy on Attentional Blink task, with higher accuracy indicating faster processing speed. | ClinicalTrials.gov |
| Primary | Change in verbal memory | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in number recalled on Hopkins Verbal Learning Task, with greater number of items recalled indicating better verbal memory. | ClinicalTrials.gov |
| Primary | Change in visuospatial function | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in accuracy on Benton Judgement of Line Orientation task, with higher accuracy indicating better visuospatial function. | ClinicalTrials.gov |
| Primary | Change in white matter integrity | Baseline (M0), 6-month follow-up (M6) | Change in fractional anisotropy as measured by diffusion MRI. | ClinicalTrials.gov |
| Primary | Change in brain volume | Baseline (M0), 6-month follow-up (M6) | Change in mean cortical thickness of brain regions of interest as measured by an anatomical MRI brain scan. | ClinicalTrials.gov |
| Primary | Change in resting state functional connectivity | Baseline (M0), 6-month follow-up (M6) | Change in within-network pairwise correlation estimates as measured using a multiband echo planar imaging (mb-EPI) functional MRI sequence. | ClinicalTrials.gov |
| Primary | Change in self-reported cognitive function | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | The perceived cognitive impairments subscale of the Functional Assessment in Cancer Therapy - Cognition (FACT-Cog) will be sued to measure self-reported cognition. Scores range from 0-72, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Secondary | Change in appendicular lean mass index | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in appendicular lean mass index (ALMI) as measured by dual-energy X-ray absorptiometry (DXA) with higher scores indicating more lean mass. Appendicular lean mass, as measured by DXA, will be divided by height to determine ALMI. ALMI score is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Secondary | Change in physical function | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | The Short Physical Performance Battery (SPPB) will be used to assess physical function. Higher scores on the SPPB are indicative of better physical function. The SPPB has a minimum score of 0 and a maximum score of 12. | ClinicalTrials.gov |
| Secondary | Change in functional capacity | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | The Six Minute Walk Test (6MWT) will be used to measure functional capacity. The 6MWT is scored as distance walked in the 6 minutes with greater distance indicating greater functional capacity. | ClinicalTrials.gov |
| Secondary | Change in upper body strength | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in grip strength as measured by hand grip dynamometry with higher scores indicating greater upper body strength. Hand grip strength is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Secondary | Change in lower body strength | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in quadriceps strength as measured by hand-held quadriceps dynamometry with higher scores indicating greater lower body strength. Quadriceps strength is a continuous variable with no minimum or maximum value. | ClinicalTrials.gov |
| Secondary | Change in physical activity | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | Change in daily minutes of moderate to vigorous physical activity (MVPA) will be measured via accelerometry with more minutes of daily MVPA indicating more physical activity. | ClinicalTrials.gov |
| Secondary | Change in cancer-related fatigue | Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12) | The Functional Assessment in Chronic Illness Therapy (FACIT) - Fatigue Scale will be used to measure cancer-related fatigue. Scores range from 0-52, with higher scores indicating less cancer-related fatigue. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Primary outcome | ConductCognition |
| 2-Back Task | Primary outcome | ConductCognition |
| Attentional Blink Task | Primary outcome | ConductCognition |
| Spatial Working Memory | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)